Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy

Pharmacogenomics

Volumn 9, Issue 9, 2008, Pages 1237-1250

  Spreafico, Marta ^a   Lodigiani, Corrado ^b   van Leeuwen, Y ^c   Pizzotti, Denise ^d   Rota, Lidia L ^b   Rosendaal, F R ^c   Mannucci, Pier M ^a   Peyvandi, Flora ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SAN PAOLO HOSPITAL   (Italy)

Author keywords

Aenocoumarol; Anticoagulant therapy; Combined genotypes; CYP2C9; Dose requirement; INR; International Normalized Ratio; Pharmacogenetics; VKORC1

Indexed keywords

ACENOCOUMAROL; CYTOCHROME P450 2C9; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ACUTE CORONARY SYNDROME; ADULT; AGED; ALLELE; ANTICOAGULATION; ARTERY EMBOLISM; ARTICLE; CAUCASIAN; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART ATRIUM FIBRILLATION; HOMOZYGOSITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; ITALY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC VARIATION; HAPLOTYPES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PROSPECTIVE STUDIES;

EID: 55449133425     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.9.1237     Document Type: Article

References (55)

1. Rojas JC, Aguilara B, Rodrìguez-Maldonado E, Colladosa MT. Pharmacogenetics of oral anticoagulants. Blood Coagul. Fibrinolysis 16, 389-398 (2005).
2. Ridker PM, Goldhaber SZ, Danielson E et al.: Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N. Engl. J. Med. 48, 1425-1434 (2003).
3. Hirsh J, Dalen JE, Anderson DR et al.: Oral anticoagulants. Mechanisms of action, clinical effectiveness, and optimal therapeutic range. Chest 114, S445-S469 (1998).
4. Evans W, Relling M: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
5. Takahashi H, Echizen H: Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 40, 587-603 (2001).
6. Visser LE, van Vliet M, van Schaik RH et al.: The risk of overanticoagulation in patients with cytochrome P450 2C9*2 and CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14, 27-33 (2004).
7. Ufer M: Comparative pharmacokinetics of vitamin K antagonists warfarin, phenprocoumon and acenocoumarol. Clin. Pharmacokinet. 44, 1227-1246 (2005).
8. Thijssen HH, Flinois JP, Beaune PH: Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab. Dispos. 28, 1284-1290 (2000).
9. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korsekwa KR: Impaired S-warfarin metabolism catalyzed by R144C allelic variant of CYP2C9. Pharmacogenetics 4, 39-42 (1994).
10. Sullivan-Klose TH, Ghanayem BI, Bell DA et al.: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341-349 (1996).
11. Mark L, Marki-Zay J, Paragh G, Katona A: Retrospective analyses of acenocoumarol doses and bleeding complications in patients with wild type or variant cytochrome P450 CYP2C9 alleles. Thromb. Haemost. 93, 396-397 (2005).
12. Thijssen HH, Verkooijen IW, Frank HL: The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. [i Pharmacogenetics 10, 757-760 (2000).
13. Morin S, Bodin L, Loriot MA et al.: Pharmacogenetics of acenocoumarol pharmacodynamics. Clin. Pharmacol. Ther. 75, 403-414 (2004).
14. Schalekamp T, van Geest-Daalderop JH, de Vries-Goldschmeding H, Conemans J, Bernsen MJ M, de Boer A: Acenocoumarol stabilization is delayed in CYP2C9*3 carriers. Clin. Pharmacol. Ther. 75, 394-402 (2004).
15. Hermida J, Zarza J, Alberca I et al.: Differential effects of 2C9*3 and 2C9*2 of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 99, 4237-4239 (2002).
16. Tassies D, Freire C, Pijoan J et al.: Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 87, 1185-1191 (2002).
17. Spreafico M, Peyvandi F, Pizzotti D, Moia M, Mannucci PM: Warfarin and acenocouamrol dose requirements according to CYP2C9 genotyping in North-Italian patients. J. Thromb. Haemost. 1, 2252-2253 (2003).
18. Gage BF, Eby CS: The genetics of vitamin K antagonists. Pharmacogenomics J. 4, 224-225 (2004).
19. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 427, 541-544 (2004).
20. Rost S, Fregin A, Ivaskevicius V et al.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541 (2004).
21. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
22. Geisen C, Watzka M, Sittinger K et al.: VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost. 94, 773-779 (2005).
23. Wadelius M, Chen LY, Downes K et al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
24. Sconce EA, Khan TI, Wynne HA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
25. Aquilante CL, Langaee TY, Lopez LM et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79, 291-302 (2006).
26. Mushiroda T, Ohnishi Y, Saito S et al.: Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J. Hum. Genet. 51, 249-253 (2006).
27. Caldwell MD, Berg RL, Zhang KQ et al.: Evaluation of genetic factors for warfarin dose prediction. Clin. Med. Res. 5, 8-16 (2007).
28. Bodin L, Verstuyft C, Tregouet DA et al.: Cytochrome P450 2C9 ( CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106, 135-140 (2005).
29. Schalekamp T, Brassé BP, Roijers JF et al.: VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin. Pharmacol. Ther. 80, 13-22 (2006).
30. Gonzalez-Conejero R, Corral J, Roldan V et al.: The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J. Thromb. Haemost. 5, 1701-1706 (2007).
31. Schwarz UI, Ritchie MD, Bradford Y et al.: Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358, 999-1008 (2008).
32. Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG: Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica 86, 1060-1070 (2001).
33. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215 (1988)
34. Taube J, Halsall D, Baglin T: Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96, 1816-1819 (2000).
35. D'Andrea G, D'Ambrosio RL, Di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005).
36. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL: Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 91, 87-94 (2004).
37. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E: A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. 69, 236-239 (1993).
38. Osman A, Enstrom C, Arbring K, Soderkvist P, Lindahl TL: Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. J. Thromb. Haemost. 4, 1723-1729 (2006).
39. Scott SA, Edelmann L, Kornreich R et al.: Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am. J. Hum. Genet. 82, 495-500 (2008).
40. Loebstein R, Dvoskin I, Halkin H et al.: A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109, 2477-2480 (2007).
41. Yuan HY, Chen JJ, Lee MT et al.: A novel functional VKORC1 promoter polymorphism is associated with interindividual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14, 1745-1751 (2005).
42. Gage B, Eby C, Johnson J et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. (2008) (Epub ahead of print) doi:10.1038/ clpt.2008.10]
43. Limdi NA, McGwin G, Goldstein JA et al.: Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin. Pharmacol. Ther. 83, 312-321 (2008).
44. Higashi MK, Veenstra DL, Kondo LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002).
45. Margaglione M, Colaizzo D, D'Andrea G et al.: Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 84, 775-778 (2000).
46. Gage BF, Lesko LJ: Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J. Thromb. Thrombolysis 25(1), 45-51 (2007).
47. Sconce EA, Kamali F: Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen. Eur. J. Haematol. 77, 457-462 (2006).
48. Carlquist JF, Horne BD, Muhlestein JB et al.: Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J. Thromb. Thrombolysis 22, 191-197 (2006).
49. Hamberg AK, Dahl ML, Barban M et al.: A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin. Pharmacol. Ther. 81, 529-538 (2007).
50. Wadelius M, Chen LY, Eriksson N et al.: Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34 (2007).
51. Takahashi H, Wilkinson GR, Nutescu EA et al.: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16, 101-110 (2006).
52. Tham LS, Goh BC, Nafziger A et al.: A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin. Pharmacol. Ther. 80, 346-355 (2006).
53. Voora D, Eby C, Linder MW et al.: Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb. Haemost. 95, 700-705 (2005).
54. Millican EA, Lenzini PA, Milligan PE et al.: Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110, 1511-1515 (2007).
55. Anderson JL, Horne BD, Stevens SM et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116, 2563-2570 (2007).